Clinical Efficacy of Oral Vorinostat Combined with Lenalidomide and Dexamethasone in a Patient with Refractory End-Stage Multiple Myeloma – a Patient Case Study
Davi D Siegel , Karly Olivo
Blood 112 ( 11) 5218 -5218
2008
Responses and Survival Are Not Affected by Cytogenetics In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM) Treated with Single-Agent Carfilzomib
Thomas Martin , Seema B. Singhal , Michael Wang , Ravi Vij
Blood 116 ( 21) 1942 -1942
3
2010
Long-Term Treatment and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
Sundar Jagannath , Ravi Vij , Jonathan L. Kaufman , Thomas Martin
Blood 116 ( 21) 1953 -1953
9
2010
Pooled Safety Analysis From Phase (Ph) 1 and 2 Studies of Carfilzomib (CFZ) In Patients with Relapsed and/or Refractory Multiple Myeloma (MM)
Seema B. Singhal , David Samuel diCapua Siegel , Thomas Martin , Ravi Vij
Blood 116 ( 21) 1954 -1954
12
2010
Results of PX-171-003-A1, An Open-Label, Single-Arm, Phase 2 (Ph 2) Study of Carfilzomib (CFZ) In Patients (pts) with Relapsed and Refractory Multiple Myeloma (MM)
David Samuel diCapua Siegel , Thomas Martin , Michael Wang , Ravi Vij
Blood 116 ( 21) 985 -985
37
2010
Phase 1b Evaluation of the Safety and Efficacy of a 30-Minute IV Infusion of Carfilzomib In Patients with Relapsed and/or Refractory Multiple Myeloma
Kyriakos Papadopoulos , David Samuel diCapua Siegel , Seema B. Singhal , Jeffrey R. Infante
Blood 116 ( 21) 3024 -3024
7
2010
Baseline Peripheral Neuropathy Does Not Impact the Efficacy and Tolerability of the Novel Proteasome Inhibitor Carfilzomib (CFZ): Results of a Subset Analysis of a Phase 2 Trial In Patients with Relapsed and Refractory Multiple Myeloma (R/R MM)
Thomas Martin , Seema B. Singhal , Ravi Vij , Michael Wang
Blood 116 ( 21) 3031 -3031
11
2010
Vorinostat Overcomes Lenalidomide-Dexamethasone and Lenalidomide-Bortezomib-Dexamethasone Resistance In Relapsed/Refractory Multiple Myeloma
David Samuel diCapua Siegel , Laura McBride , Elizabeth Bilotti , Linda Schmidt
Blood 116 ( 21) 3065 -3065
9
2010
Lenalidomide Plus Low-Dose Dexamethasone (Ld): Superior One and Two Year Survival Regardless of Age Compared to Lenalidomide Plus High-Dose Dexamethasone (LD)
David H. Vesole , Susanna Jacobus , S. Vincent Rajkumar , Rafat Abonour
Blood 116 ( 21) 308 -308
9
2010
Outcome with Lenalidomide Plus Dexamethasone Followed by Early Autologous Stem Cell Transplantation In the ECOG E4A03 Randomized Clinical Trial
David Samuel diCapua Siegel , Susanna Jacobus , S. Vincent Rajkumar , Rafat Abonour
Blood 116 ( 21) 38 -38
31
2010
The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.
Sandra Wear , Paul G. Richardson , Carolyn Revta , Ravi Vij
Blood 116 ( 21) 3803 -3803
1
2010
Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy
Jens G. Lohr , Petar Stojanov , Scott L. Carter , Peter Cruz-Gordillo
Cancer Cell 25 ( 1) 91 -101
1,021
2014
IgA Monoclonal Gammopathy of Undetermined Significance and Complication of Streptococcus mitis Bacteremia.
Jennifer Paterno , Alessandra Petrillo , David Samuel Dicapua Siegel , Chinwe Ogedegbe
Case reports in hematology 2020 8823908
2020
EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001
X. Leleu , M. Beksac , T. Chou , M.A. Dimopoulos
Hematology, Transfusion and Cell Therapy 42 257 -258
2020
Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma
Andrzej J. Jakubowiak , Don M. Benson , William Bensinger , David S.D. Siegel
Journal of Clinical Oncology 30 ( 16) 1960 -1965
173
2012
Interim results from PX-171-006, a phase (Ph) II multicenter dose-expansion study of carfilzomib (CFZ), lenalidomide (LEN), and low-dose dexamethasone (loDex) in relapsed and/or refractory multiple myeloma (R/R MM).
M. Wang , W. Bensinger , T. Martin , M. Alsina
Journal of Clinical Oncology 29 8025 -8025
17
2011
PX-171-003-A1, an open-label, single-arm, phase (Ph) II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): Long-term follow-up and subgroup analysis.
D. S. D. Siegel , T. Martin , M. Wang , R. Vij
Journal of Clinical Oncology 29 8027 -8027
9
2011
The association between the GOELAMS MCL-PET prognostic index and survival in patients treated with rituximab-hypercvad (R-HyCVAD) or high-dose therapy with autologous stem cell rescue (HDT/ASCT).
T. Feldman , A. R. Mato , T. Zielonka , S. D. Rowley
Journal of Clinical Oncology 29 8050 -8050
2011
A new predictive model based on age, pretreatment LDH, and post-therapy PET-CT in patients with MCL treated with dose-intensive strategies.
A. R. Mato , T. Feldman , T. Zielonka , S. Goldberg
Journal of Clinical Oncology 29 8051 -8051
1
2011
A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).
P. Moreau , A. P. Palumbo , A. K. Stewart , V. Rajkumar
Journal of Clinical Oncology 29
21
2011